A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors

This study is divided into two phases: Phase Ia and Phase Ib.

Dose-Escalation and Expansion:

• Phase Ia: This dose-escalation phase involves both single-dose and multiple-dose administrations of NK042 in patients with advanced solid tumors.
• Phase Ib: This multiple-dose cohort-expansion phase will focus on solid tumor indications that demonstrated preliminary efficacy in Phase Ia.

Inclusion criteria

• Voluntary signing of a written informed consent form.
• Age between 18 and 70 years.
• Histologically or cytologically confirmed locally advanced or metastatic solid tumor patients who are not amenable to surgical resection, with no standard treatment options, or who have relapsed or progressed after standard treatment, or are resistant or intolerant to standard treatment.
• At least one assessable tumor lesion according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
• Expected survival ≥12 weeks.
• Must have adequate bone marrow, liver, and renal function.

Exclusion criteria

• Insufficient washout period for prior anti-tumor treatments before the first dose, including chemotherapy, targeted therapy, antibody therapy, and radiotherapy.
• Participation in another clinical trial and use of investigational drugs within 28 days before the first dose.
• Requirement for anticoagulation therapy.
• Symptomatic brain parenchymal metastases with less than 4 weeks of stability after treatment.
• Active pulmonary diseases, including but not limited to interstitial lung disease, pneumonitis.
• Uncontrolled active infections.
• Uncontrollable massive pleural effusion, ascites, or pericardial effusion.
• Previous receipt of other cellular therapies.
• Planned concurrent participation in other anti-tumor treatments during the study.
• Pregnant or breastfeeding women.